A multibillion-dollar crypto asset manager cites several reasons for the bitcoin plunge, but he's listing "the four-year cycle" as the No. 1 downward catalyst. According to Matt Hougan, chief ...

CNBC’s “Closing Bell Overtime” team discusses why bitcoin is down 17% so far in February 2026 with Hunter Horsley, CEO of Bitwise Asset Management. Got a confidential news tip? We want to hear from ...

Crypto has been in a full-blown winter since January 2025, even if much of the market has been reluctant to say it out loud, asset manager Bitwise said in a Monday blog post. Having lived through ...

This ETF is a nifty way to gain cryptocurrency exposure. It's potential-rich, but prospective investors need to look under the hood. Some of its holdings are spreading their wings beyond crypto.

Bitwise's first vault strategy with Morpho will aim to generate up to 6% APY1 on stablecoins, with plans to expand into several other strategies. Vaults are onchain lending strategies that function ...

Retail crypto's mood is "extraordinarily negative," but institutional investors are "unremittingly bullish," according to Bitwise Asset Mangement's Matt Hougan. Amberdata's Greg Magadini expects ...

Bitwise MSTR Option Income Strategy ETF (IMST) - $1.31. Payable Dec 29, 2025; for shareholders of record Dec 25, 2025; ex-div Dec 25, 2025. More on Bitwise MSTR Option Income Strategy ETF Seeking ...

The items were taken in the late 19th century from what was then called the Dutch East Indies. Indonesia had been trying to get them back for decades. By Nina Siegal Reporting from Amsterdam The ...

Bitwise is telling clients to brace for a different kind of bitcoin BTC $63,233.47 market in 2026, arguing that the asset is maturing just as institutional money ramps up. The crypto asset manager ...

Bank of America has joined other large institutions in expanding access to cryptocurrencies, with the wirehouse allowing Merrill Lynch advisors to include certain crypto exchange-traded products in ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...